A selective small-molecule nuclear factor-κB inhibitor from a high-throughput cell-based assay for “activator protein-1 hits”

  title={A selective small-molecule nuclear factor-$\kappa$B inhibitor from a high-throughput cell-based assay for “activator protein-1 hits”},
  author={Moon-Il Kang and Curtis J. Henrich and Heidi R Bokesch and Kirk R. Gustafson and James B. Mcmahon and Alyson R. Baker and Matthew R. Young and Nancy H. Colburn},
  journal={Molecular Cancer Therapeutics},
  pages={571 - 581}
NSC 676914 has been identified as a selective nuclear factor-κB (NF-κB) inhibitor that does not inhibit cell proliferation. This compound was originally identified in a high-throughput cell-based assay for activator protein-1 (AP-1) inhibitors using synthetic compound libraries and the National Cancer Institute natural product repository. NSC 676914 shows activity against NF-κB in luciferase reporter assays at concentrations much less than the IC50 for AP-1. A serum response element reporter… 

Figures from this paper

Screening a small molecule library to identify inhibitors of NF-κB inducing kinase and pro-labor genes in human placenta

It is found that 14 drugs have selective inhibitory activity against lymphotoxin beta complex-induced activation of RelB/p52 in HEK293T cells, several of which also inhibited expression of CRH and COX-2 in human term trophoblast.

A cell-penetrating peptide suppresses inflammation by inhibiting NF-κB signaling.

The results suggest that AIP6 is a promising lead peptide for the development of specific NF-κB inhibitors as potential anti-inflammatory agents.

Identification and Characterization of a Novel Class of c-Jun N-terminal Kinase Inhibitors

It is concluded that compounds with an indenoquinoxaline nucleus can serve as specific small-molecule modulators for mechanistic studies of JNKs as well as a potential leads for the development of anti-inflammatory drugs.

Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.

Niclosamide inhibited the NF-kappaB pathway and increased ROS levels to induce apoptosis in AML cells and these results support further investigation of niclosamide in clinical trials of AML patients.

FOXO3–NF-κB RelA Protein Complexes Reduce Proinflammatory Cell Signaling and Function

This study demonstrates a novel mechanism involving FOXO3 and NF-κB RelA that controls myeloid cell signaling and impacts their immune-suppressive nature and identifies for the first time, to the knowledge, a direct protein–protein interaction in tumor-associated DCs.

Bioactivities of six sterols isolated from marine invertebrates

The bioactive and unstable steroid should be biosynthesized in sponge under a special ecological environment to act as a defensive strategy against invaders.

Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors

Pharmacodynamics data demonstrate that γδ T lymphocyte amplification in humans requires the co-administration of IL-2 and is dependent on IPH 1101 dose, which indicates IPH1101 in combination with SC low-dose IL- 2 is safe, well tolerated and induces a potent γ Δ T lymphocytes expansion in patients.

BRITER: A BMP Responsive Osteoblast Reporter Cell Line

The cell line, named BRITER (BMP Responsive Immortalized Reporter cell line), responds robustly, promptly and specifically to exogenously added BMP2 protein, which may be used effectively for chemical or molecular genetic screening for BMP signaling modifiers.



A High-Throughput Cell-Based Assay to Identify Specific Inhibitors of Transcription Factor AP-1

A high-throughput assay to screen synthetic and natural product libraries for noncytotoxic inhibitors of mitogen-activated AP-1 activity and identified hits from a range of taxonomic groups.

BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice*

The BMS-345541 compound is effective against NF-κB activation in mice and represents an important tool for investigating the role of IKK in disease models.

Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.

The mouse model enriches for TAM67 targets relevant to tumorigenesis rather than to general cell proliferation or hyperplasia, implicating a subset of AP-1- and/or NFkappaB-dependent genes.

Transcriptional activation of the NF‐κB p65 subunit by mitogen‐ and stress‐activated protein kinase‐1 (MSK1)

It is shown that the mitogen‐activated protein kinase inhibitors SB203580 and PD98059 or U0126, as well as a potentMitogen‐ and stress‐ activatedprotein kinase‐1 (MSK1) inhibitor H89, counteract tumor necrosis factor (TNF)‐mediated stimulation of p65 transactivation capacity.

NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors.

A perspective is presented, proposing de novo design of inhibitors which directly interact with the DNA Binding region of the free NF-kappaB (p50 subunit), so as to generate more specific and selective leads of NF- kappaB-DNA binding.

AP-1, NF-kappa-B, and ERK activation thresholds for promotion of neoplastic transformation in the mouse epidermal JB6 model.

The findings suggest that the signaling pathway leading to the activation of ERK, TCF, and AP-1 proteins constitutes a major factor determining the risk of tumor promotion by TPA or EGF.

Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation

It is shown that TPA induction of the architectural transcription factor HMGA1 is inhibited by TAM67, is extracellular–signal-regulated kinase (ERK)-activation dependent, and is mediated by AP-1.

Repression of Inflammatory Gene Expression in Human Pulmonary Epithelial Cells by Small-Molecule IκB Kinase Inhibitors

The above data provide strong support for an anti-inflammatory effect of IKK2 inhibitors acting on the pulmonary epithelium and suggest that such compounds may prove beneficial in situations where traditional corticosteroid therapies prove inadequate.

NF-κB as a Therapeutic Target in Multiple Myeloma*

These studies demonstrate that specific targeting of NF-κB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu.